Gilead Sciences (GILD)

Gilead Sciences has filed an appeal in the Indian Intellectual Property Appellate Board (IPAB) to challenge a recent order by an Indian Patent Office that rejected two patent claims for its best seller drug Viread (tenofovir disoproxil fumarate).
In August, the Indian Patent Office in Delhi rejected two patents sought by the firm for Viread after patient groups and Indian company Cipla challenged its patentability.

Dec 8 · 3:14:00 PM · Source: The Economic Times
Track · email · face · Twitter · digg · COMMENTS
by Michael Oliveto